Accessibility setting


Select language

Skip to secondary menu

Skip to content

Jehovah’s Witnesses


Neonatal Medicine

Erythropoiesis-Stimulating Agents (ESAs) in Neonates

Early erythropoietin administration does not increase the risk of retinopathy in preterm infants.

Chou HH, Chung MY, Zhou XG, Lin HC

Source‎: Pediatr Neonatol 2016 Jun. [Epub ahead of print.]

Indexed‎: PubMed 27346390

DOI‎: 10.1016/j.pedneo.2016.03.006

Association between early administration of high-dose erythropoietin in preterm infants and brain MRI abnormality at term-equivalent age.

Leuchter RH, Gui L, Poncet A, Hagmann C, Lodygensky GA, Martin E, Koller B, Darqué A, Bucher HU, Hüppi PS.

Source‎: JAMA 2014;312(8):817-24.

Indexed‎: PubMed 25157725

DOI‎: 10.1001/jama.2014.9645

Cognitive outcomes of preterm infants randomized to darbepoetin, erythropoietin, or placebo.

Ohls RK, Kamath-Rayne BD, Christensen RD, Wiedmeier SE, Rosenberg A, Fuller J, Lacy CB, Roohi M, Lambert DK, Burnett JJ, Pruckler B, Peceny H, Cannon DC, Lowe JR.

Source‎: Pediatrics 2014;133(6):1023-30.

Indexed‎: PubMed 24819566

DOI‎: 10.1542/peds.2013-4307

A randomized, masked, placebo-controlled study of darbepoetin alfa in preterm infants.

Ohls RK, Christensen RD, Kamath-Rayne BD, Rosenberg A, Wiedmeier SE, Roohi M, Lacy CB, Lambert DK, Burnett JJ, Pruckler B, Schrader R, Lowe JR.

Source‎: Pediatrics 2013;132(1):e119-27.

Indexed‎: PubMed 23776118

DOI‎: 10.1542/peds.2013-0143

Effect of short-term recombinant human erythropoietin therapy in the prevention of anemia of prematurity in very low birth weight neonates.

Yasmeen BH, Chowdhury MA, Hoque MM, Hossain MM, Jahan R, Akhtar S.

Source‎: Bangladesh Med Res Counc Bull 2012;38(3):119-23.

Indexed‎: PubMed 23540189

How to administrate erythropoietin, intravenous or subcutaneous?

Costa S, Romagnoli C, Zuppa AA, Cota F, Scorrano A, Gallini F, Maggio L.

Source‎: Acta Paediatr 2013;102(6):579-83.

Indexed‎: PubMed 23414120

DOI‎: 10.1111/apa.12193

Decrease in incidence of bronchopulmonary dysplasia with erythropoietin administration in preterm infants: a retrospective study.

Rayjada N, Barton L, Chan LS, Plasencia S, Biniwale M, Bui KC.

Source‎: Neonatology 2012;102(4):287-92.

Indexed‎: PubMed 22922736

DOI‎: 10.1159/000341615

Outcomes of extremely low birth weight infants given early high-dose erythropoietin.

McAdams RM, McPherson RJ, Mayock DE, Juul SE.

Source‎: J Perinatol 2013;33(3):226-30.

Indexed‎: PubMed 22722674

DOI‎: 10.1038/jp.2012.78

Use of recombinant human erythropoietin and risk of severe retinopathy in extremely low-birth-weight infants.

Schneider JK, Gardner DK, Cordero L.

Source‎: Pharmacotherapy 2008;28(11):1335-40.

Indexed‎: PubMed 18956993

DOI‎: 10.1592/phco.28.11.1335

An approach to using recombinant erythropoietin for neuroprotection in very preterm infants.

Fauchère JC, Dame C, Vonthein R, Koller B, Arri S, Wolf M, Bucher HU.

Source‎: Pediatrics 2008;122(2):375-82.

Indexed‎: PubMed 18676556

DOI‎: 10.1542/peds.2007-2591

The medical section of is designed as an informational resource primarily for use by clinicians and other health-care professionals. It provides neither medical advice nor treatment recommendations and does not substitute for an appropriately qualified health-care provider. The clinical literature cited is not published by Jehovah’s Witnesses, but it outlines transfusion-alternative strategies that might be considered. It is the responsibility of each qualified health-care provider to maintain awareness of new information, discuss options for care, and assist patients in making choices in accord with their medical condition, wishes, values, and beliefs. Not all listed strategies are appropriate or acceptable to all patients.

Patients: Always seek the advice of your doctor or other qualified health-care provider regarding medical conditions or treatments. Check with a doctor if you suspect you are ill.

The use of this website is governed by its terms of use.